netFormulary NHS
Sunderland Joint Formulary
NHS Sunderland Clinical Commissioning Group
South Tyneside and Sunderland NHS Foundation Trust
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Chapter Links...
 Details...
08.01  Cytotoxic drugs
08.01  Side-effects of cytotoxic drugs
08.01  Drugs for cytotoxic-induced side-effects
Calcium Folinate (Folinic acid)
View adult BNF View SPC online
Formulary
Red

Tablets: 15mg
Injection: 3mg, 15mg, 30mg and 300mg
An unlicensed 1mg per 1ml mouthwash can be prepared if needed unlicensedunlicensed 

 
   
Dexrazoxane (Savene®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Vials: 500mg (with diluent)
- for use in line with NECN extravasation

 
   
Glucarpidase
View adult BNF View SPC online
Formulary
Red

unlicensedunlicensed Vials: 1000units -approved for the urgent treatment of methotrexate-induced renal dysfunction (subject to NHS England funding)

 
   
Mesna
View adult BNF View SPC online
Formulary
Red

Injection: 1g in 10ml
Tablets: 400mg

 
   
Pegasparagase
View adult BNF View SPC online
Formulary
Red

Vial: 3750 international units

 
Link  NICE TA 408: Pegaspargase for treating acute lymphoblastic leukaemia
   
08.01.01  Alkylating drugs
Cytotoxic Drug Bendamustine
View adult BNF View SPC online
Formulary
Red
Cancer Drugs Fund

Injections: 25mg & 100mg


-approved for the first line treatment of CLL (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate in line with NICE


-NECDAG approved for use in combination with rituximab for patients with CLL not fit for FCR chemotherapy and not fit for alemtuzumab.


-approved for Low Grade Non-Hodgkins Lymphoma in line with NICE -not recommended for (low grade) non-Hodgkin's lymphoma that is refractory to rituximab or a rituximab-containing regimen NICE

 
Link  NICE TA216: Bendamustine for CLL
   
Cytotoxic Drug Busulfan
View adult BNF View SPC online
Formulary
Red

Tablets: 2mg
Injection: 60mg in 10ml
unlicensedunlicensed Capsules: 25mg

 
   
Cytotoxic Drug Carmustine (BiCNU®)
View adult BNF View SPC online
Formulary
Red

Implants: 7.7mg

 
Link  NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
   
Cytotoxic Drug Chlorambucil
View adult BNF View SPC online
Formulary
Red

Tablets: 2mg

 
   
Cytotoxic Drug Cyclophosphamide
View adult BNF View SPC online
Formulary
Red

Tablets: 50mg 
Injection: 1g

 
   
Cytotoxic Drug Estramustine
View adult BNF View SPC online
Formulary
Red

Capsules: 140mg

 
   
Cytotoxic Drug Ifosfamide
View adult BNF View SPC online
Formulary
Red

Injection: 2g

 
   
Cytotoxic Drug Lomustine
View adult BNF View SPC online
Formulary
Red

Capsules: 40mg
unlicensedunlicensed capsules: 10mg

 
   
Cytotoxic Drug Melphalan
View adult BNF View SPC online
Formulary
Red

Tablets: 2mg
Injection: 50mg

 
   
Cytotoxic Drug Thiotepa
View adult BNF View SPC online
Formulary
Red

Injection: 15mg

 
   
Treosulfan
View adult BNF View SPC online
Formulary
Red
NHS England

Infusion: 1g and 5g

 
Link  NICE TA 640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant
   
08.01.02  Anthracyclines and other cytotoxic antibiotics to top
Cytotoxic Drug Bleomycin
View adult BNF View SPC online
Formulary
Red

Injection: 15,000 units (strength formerly expressed as 15mg)
-unlicensedunlicensed also approved for use in intralesional sclerotherapy in the treatment of low-flow vascular lesions – unlicensed indication

 
   
Cytotoxic Drug Dactinomycin
View adult BNF View SPC online
Formulary
Red

Injection: 500 microgram

 
   
Cytotoxic Drug Daunorubicin
View adult BNF View SPC online
Formulary
Red

Injection: 20mg
Prefilled syringes: 10mg, 15mg, 35mg & 40mg

 
   
Cytotoxic Drug Doxorubicin Hydrochloride
View adult BNF View SPC online
Formulary
Red

Injection: 50mg
- includes use with DC Beads for use in transcatheter arterial chemoembolisation (TACE) therapy in patients with hepatocellular cancer

Pegylated liposomal injection: 20mg & 50mg
-approved for the treatment of recurrent ovarian cancer in line with NICE

 
Link  NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
Cytotoxic Drug Epirubicin hydrochloride
View adult BNF View SPC online
Formulary
Red

Injections: 50mg
unlicensedunlicensed Injection: 100mg  

 
   
Cytotoxic Drug Idarubicin Hydrochloride
View adult BNF View SPC online
Formulary
Red

Capsules: 5mg & 10mg
Injection: 10mg

 
   
Cytotoxic Drug Mitomycin
View adult BNF View SPC online
Formulary
Green +

unlicensedunlicensed Preservative free eye drop: 0.04% preservative free eye drops

 
   
Cytotoxic Drug Mitomycin
View adult BNF View SPC online
Formulary
Red

Injection: 10mg, 20mg & 40mg
- Also approved for treatment in combination with 5-Fluorouracil for bladder cancer concurrent with radiotherapy.

 
   
Cytotoxic Drug Mitoxantrone
View adult BNF View SPC online
Formulary
Red

Injection: 20mg in 10ml

 
   
Cytotoxic Drug Pixantrone
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Injection: 29mg powder for reconstitution injection
-approved as a possible treatment for adults with multiply relapsed or refractory aggressive non-Hodgkin's B cell lymphoma if they have previously been treated with rituximab and they are having third- or fourth-line treatment NICE

 
Link  NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma
   
08.01.03  Antimetabolites
Cytotoxic Drug Azacitidine (Vidaza®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Vial: 100mg

 
Link  NICE TA 399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
Link  NICE TA218: azacitidine for myelodysplastic syndromes
   
Cytotoxic Drug Capecitabine
View adult BNF View SPC online
Formulary
Red

Tablets: 150mg & 500mg

 
Link  NICE TA 212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Link  NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Link  NICE TA191: Gastric cancer (advanced) - capecitabine
Link  NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
Link  NICE TA60: Colorectal cancer - capecitabine and tegafur uracil
   
Cytotoxic Drug Cladribine
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Solution for preparing infusions: 10mg in 10ml
Subcutaneous injection: 2mg in 1ml
- approved for Hairy Cell Leukemia

Tablets: 10mg

 as an option for relapsing-remitting multiple sclerosis as per NICE (see link)

 
Link  NICE TA616
   
Cytotoxic Drug Cytarabine
View adult BNF View SPC online
Formulary
Red

Injections: 100mg in 5ml, 1g in 10ml
Vial: 50mg (cytarabine encapsulated in liposomes)

 
   
Cytotoxic Drug Daunorubicin/ cytarabine (Vyxeos)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
  • Approved for untreated acute myeloid leukaemia in line with NICE 
  • Link  NICE TA 552: Liposomal cytarabine - daunorubicin for untreated acute myeloid leukaemia
       
    Cytotoxic Drug Fludarabine
    View adult BNF View SPC online
    Formulary
    Red

    Tablets: 10mg
    Injection: 50mg

     
    Link  NICE TA119: Leukaemia (lymphocytic) - fludarabine
    Link  NICE TA29: Leukaemia (lymphocytic) - fludarabine
       
    Cytotoxic Drug Fluorouracil
    View adult BNF View SPC online
    Formulary
    Red

    Injections: 2.5g in 50ml & 2.5g in 100ml
    unlicensedunlicensed Subconjunctival injection: 10mg in 0.4ml
    (FOLFIRINOX is approved for the management of selected patients with inoperable pancreatic cancer in patients with performance status 0-1).

     
       
    Cytotoxic Drug Gemcitabine
    View adult BNF View SPC online
    Formulary
    Red

    Injection: 200mg, 1g, 2g

     
    Link  NICE NG85: Pancreatic cancer - gemcitabine
    Link  NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
    Link  NICE TA116: Breast cancer - gemcitabine
       
    Cytotoxic Drug Mercaptopurine
    View adult BNF View SPC online
    Formulary
    Red

    Tablets: 50mg
    unlicensedunlicensed Suspension: 20mg in 1ml


     


    Note, mercaptopurine is amber if used for inflammatory bowel disease

     
       
    Cytotoxic Drug Methotrexate
    View adult BNF View SPC online
    Formulary
    Red

    Tablets: 2.5mg
    unlicensedunlicensed Oral solution: 10mg in 5ml
    unlicensedunlicensed Injections (various strengths) – including prefilled syringes
    Intrathecal injection: 5mg in 2ml

     

    Note, methotrexate is amber if used in chronic inflammarory conditions, e.g. Crohn's disease, rheumatoid arthritis

     
       
    Cytotoxic Drug Pemetrexed
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Injection: 100mg & 500mg

     
    Link  NICE TA 402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
    Link  NICE TA124: Lung cancer (non-small-cell) - pemetrexed
    Link  NICE TA135: Mesothelioma - pemetrexed disodium
    Link  NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
    Link  NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
       
    Cytotoxic Drug Tegafur with Uracil (Uftoral®)
    View adult BNF View SPC online
    Formulary
    Red

    Capsules:  containing tegafur 100mg & uracil 224mg

     
    Link  NICE TA61: Capcitabine and tegafur - Colorectal cancer
       
    08.01.04  Vinca alkaloids and etoposide
    Etoposide
    View adult BNF View SPC online
    Formulary
    Red

    Capsules: 50mg & 100mg
    Injections: 100mg in 5ml & 500mg in 25ml

     
       
    Cytotoxic Drug Vinblastine
    View adult BNF View SPC online
    Formulary
    Red

    Injection: 10mg

     
       
    Cytotoxic Drug Vincristine
    View adult BNF View SPC online
    Formulary
    Red

    Injection: 2mg in 2ml
    Prefilled syringe: 2mg in 20ml
    Infusion bags: 2mg in 50ml

     
       
    Cytotoxic Drug Vindesine Sulphate
    View adult BNF View SPC online
    Formulary
    Red

    Injection: 5mg

     
       
    Cytotoxic Drug Vinorelbine
    View adult BNF View SPC online
    Formulary
    Red

    Capsules: 20mg, 30mg
    Injections: 10mg in 1ml & 50mg in 5ml

     
       
    08.01.05  Other antineoplastic drugs
    Cytotoxic Drug Aflibercept (Zaltrap®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Vials: 100mg/4ml, 40mg/1ml

     
    Link  NICE TA 294: Aflibercept solution for injection for treating wet age‑related macular degeneration
    Link  NICE TA 305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
    Link  NICE TA 307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
    Link  NICE TA 346: Aflibercept for treating diabetic macular oedema
    Link  NICE TA 409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
    Link  NICE TA 486: Aflibercept for treating choroidal neovascularisation
       
    Atezolizumab
    View adult BNF View SPC online
    Formulary
    Red
    Cancer Drugs Fund
    NHS England

    Atezolizumab is recommended for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults, for whom cisplatin-based chemotherapy is unsuitable, only if the conditions of the managed access agreement for atezolizumab are followed

    Also available through patient access scheme for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy 
    Link  NICE TA 492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
    Link  NICE TA 520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
    Link  NICE TA 525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
    Link  NICE TA 584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
    Link  NICE TA 638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
    Link  NICE TA 639:Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
    Link  NICE TA 666:Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
       
    Avelumab Black Triangle (Bavencio ®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England

    20mg/ml concentrate for infusion.

     
    Link  NICE TA 517: Avelumab for treating metastatic Merkel cell carcinoma
    Link  NICE TA 645: Avelumab with axitinib for untreated advanced renal cell carcinoma
       
    Axicabtagene ciloleucel
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
     
    Link  NICE TA 559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after 2 or more systemic therapies
       
    Axitinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Film coated tablets: 1mg, 3mg, 5mg and 7mg

     
    Link  NICE TA 333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
       
    Bosutinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Film coated tablets: 100mg, 500mg

     
    Link  NICE TA 401: Bosutinib for previously treated chronic myeloid leukaemia
       
    Carfilzomib (Kyrolis®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Vial: powder for infusion 10 mg, 30 mg and 60 mg

     
    Link  NICE TA 657: Carfilzomib for previously treated multiple myeloma
       
    Ceritinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Capsule: 150mg

     
    Link  NICE TA 395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
    Link  NICE TA 500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
       
    Dabrafenib (Tafinlar®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Capsules: 50mg and 75mg

  • Approved for the treatment of unresectable or metastatic BRAF V600 mutation-positive melanoma in line with NICE 
  • Link  NICE TA 321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
    Link  NICE TA 396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
    Link  NICE TA 544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
       
    DaratumumabBlack Triangle (Darzalex ®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England

    20mg/ml concentrate for infusion

     
    Link  NICE TA 510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
    Link  NICE TA 573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
       
    Encorafenib (Braftovi®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Capsules: 50 mg and 75 mg

     
    Link  NICE TA 562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
    Link  NICE TA 668:Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
       
    Entrectinib
    View adult BNF View SPC online
    Formulary
    Red
    Cancer Drugs Fund
    NHS England

    Capsules: 100mg and 200mg

     
    Link  NICE TA 643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
    Link  NICE TA 644: Entrectinib for treating NTRK fusion-positive solid tumours
       
    Cytotoxic Drug Eribulin (Halaven®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Vial: 0.88mg/2ml
    Vial: 1.32mg/3ml

     
    Link  NICE TA 423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
       
    Gemtuzumab ozogamicin (Mylotarg®)
    View adult BNF View SPC online
    Formulary
    Red
  • Approved for untreated acute myeloid leukaemia in line with NICE 
  • Link  NICE TA 545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
       
    Gilteritinib (as fumarate)
    View adult BNF View SPC online
    Formulary
    High Cost Medicine
    NHS England

    Tablets: 40mg

     
    Link  NICE TA 642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
       
    Ibrutinib (Imbruvica®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Capsules: 140mg

     
    Link  NICE TA 491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
    Link  NICE TA 502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
       
    Idelalisib
    View adult BNF View SPC online
    Formulary
    Red
    Cancer Drugs Fund

    Film coated tablets: 100mg, 150mg

     
    Link  NICE TA 359: Idelalisib for treating chronic lymphocytic leukaemia
       
    Inotuzumab ozogamicin (Besponsa®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
  • Approved for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults in line with NICE 
  • Link  NICE TA 541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
       
    Ixazomib (Ninlaro®)
    View adult BNF View SPC online
    Formulary
    Red

    Capsules: 4mg

     
    Link  NICE TA 505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
       
    Cytotoxic Drug Lenvatinib (Lenvima®)
    View adult BNF View SPC online
    Formulary
    Red

    Capsules: 4mg and 10mg

     
    Link  NICE TA 498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
    Link  NICE TA 535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
    Link  NICE TA 551: Lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma
       
    Cytotoxic Drug MidostaurinBlack Triangle (Rydapt ®)
    View adult BNF View SPC online
    Formulary
    Red
    NHS England
    25mg capsules 
    Link  NICE TA 522 Midostaurin for untreated acute myeloid leukaemia
       
    Cytotoxic Drug Niraparib (Zejula®)
    View adult BNF View SPC online
    Formulary
    Red
    Cancer Drugs Fund
    Niraparib tosylate monohydrate 100mg capsules 
    Link  NICE TA 528: Niraparib for maintenance treatment of relapsed, platinum sensitive ovarian, fallopian tube and peritoneal cancer
       
    Olaparib
    View adult BNF View SPC online
    Formulary
    Red
    Cancer Drugs Fund
    NHS England

    Capsules: 50mg

    - Olaparib is recommended for use within the Cancer Drugs Fund as an option for the maintenance treatment of BRCA mutation‑positive, advanced (FIGO stages 3 and 4), high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to first-line platinum-based chemotherapy in adults. It is recommended only if the conditions in the managed access agreement for olaparib are followed

    - approved for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer in line with NICE

     
    Link  NICE TA 598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
    Link  NICE TA 620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
       
    Olaratumab
    View adult BNF View SPC online
    Formulary
    Red

    Concentrate for solution for infusion: 10 mg/mL

     
       
    Osimertinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Tablet: 40mg and 80mg

     
    Link  NICE TA 653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
    Link  NICE TA 654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
       
    Pablociclib (Ibrance®)
    View adult BNF View SPC online
    Formulary
    Red
    Cancer Drugs Fund
    NHS England

    Recommended for use according to NICE criteria

     
    Link  NICE TA 619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
       
    Panobinostat (Farydak®)
    View adult BNF View SPC online
    Formulary
    Red

    Hard capsules: 10mg, 15mg, 20mg

     
    Link  NICE TA 380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
       
    Pembrolizumab (Keytruda®)
    View adult BNF View SPC online
    Formulary
    Red
    Cancer Drugs Fund

    Concentrate for infusion: 100 mg/4 mL

    See below for NICE approved indications

     
    Link  NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
    Link  NICE TA 366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
    Link  NICE TA 428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
    Link  NICE TA 519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
    Link  NICE TA 522 Pembrolizumab for untreated locally advanced or metastatic urothelial cancer where cisplatin is unsuitable
    Link  NICE TA 531: Pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer
    Link  NICE TA 540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
    Link  NICE TA 553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
    Link  NICE TA 557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
    Link  NICE TA 600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
    Link  NICE TA 661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
       
    Polatuzumab vedotin
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Vial: 30mg and 150mg, powder for concentrate for solution for infusion.

     
    Link  NICE TA 649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
       
    Ponatinib (Iclusig®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Tablets: 15mg, 45mg

     
    Link  NICE TA 451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
       
    Radium-223 dichloride
    View adult BNF View SPC online
    Formulary
    Red
     
    Link  NICE TA 412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
       
    Rucaparib
    View adult BNF View SPC online
    Formulary
    Red
    Cancer Drugs Fund

    Film coated tablets: 200mg, 250mg, 300mg

     
    Link  NICE TA 611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
       
    Ruxolitinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Tablets: 5mg, 15mg, 20mg

     
    Link  NICE TA 386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
       
    Talimogene laherparepvec (Imlygic®)
    View adult BNF View SPC online
    Formulary
    Red

    Solution for injection: 106 plaque forming units/1ml & 108 plaque forming units/1ml


    -approved for the treatment of unresectable metastatic melanoma in line with NICE and NHS England Commissioning Policy

     
    Link  NICE TA 410: Talimogene laherparepvec for treating unresectable metastatic melanoma
       
    Tisagenlecleucel (Kymriah®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
  • Indicated for treating 'paediatric and young adult patients up to 25 years of age with B‑cell acute lymphoblastic leukaemia that is refractory, in relapse post‑transplant or in second or later relapse as per NICE

  • NICE has recommended tisagenlecleucel for use within the Cancer Drugs Fund for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies. 
  • Link  NICE TA 554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
    Link  NICE TA 567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
       
    TivozanibBlack Triangle (Fotivda® )
    View adult BNF View SPC online
    Formulary
    Red

    Capsules: 890 mg and 1340 mg

     

     
    Link  NICE TA 512: Tivozanib for treating advanced renal cell carcinoma
       
    Trametinib (Mekinist®)
    View adult BNF View SPC online
    Formulary
    Red

    Film coated tablets: 500microgram, 2mg

     
    Link  NICE TA 396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
       
    08.01.05  Amsacrine
    Cytotoxic Drug Amsacrine
    View adult BNF View SPC online
    Formulary
    Red

    Injection: 75mg in 15ml

     
       
    08.01.05  Arsenic trioxide to top
    Cytotoxic Drug Arsenic Trioxide
    View adult BNF View SPC online
    Formulary
    Red

    Ampoule: 10mg in 10ml
    -NECDAG approved relapsed or refractory acute promyelocytic leukaemia (APL)

    NICE TA for acute promyelocytic leukaemia 
    Link  NICE TA 526: Arsenic trioxide for treating acute promyelocytic leukaemia
       
    08.01.05  Bevacizumab
    Bevacizumab (Avastin®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Vial: 100mg/4ml
    Syringe: 5mg/0.2ml
    Solution for infusion: 25mg/1ml


    *Avastin is available as a treatment option for wet AMD in situations where ophthalmologists feel, in discussion with their patients, that the licensed options are unsuitable

     
    Link  NICE TA 118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
    Link  NICE TA 178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
    Link  NICE TA 212: Colorectal cancer (metastatic) - bevacizumab
    Link  NICE TA 214: Breast Cancer with taxane
    Link  NICE TA 242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
    Link  NICE TA 263: Breast cancer with capecitabine
    Link  NICE TA 284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
    Link  NICE TA 285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
       
    08.01.05  Bexarotene
    08.01.05  Bortezomib
    Cytotoxic Drug Bortezomib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Injection: 3.5mg

     
    Link  NICE TA 129: Multiple myeloma - bortezomib
    Link  NICE TA 228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
    Link  NICE TA 311: Multiple myeloma - bortezomib (induction therapy
    Link  NICE TA 370: Bortezomib for previously untreated mantle cell lymphoma
       
    08.01.05  Brentuximab vedotin
    Brentuximab vedotin (Adcetris®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England

    Vial: 50mg

     
    Link  NICE TA 524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
    Link  NICE TA 577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
    Link  NICE TA 641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
       
    08.01.05  Cetuximab to top
    Cetuximab
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Vials for IV infusion: 100mg in 20ml & 500mg in 100ml

     
    Link  NICE TA 118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
    Link  NICE TA 242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
    Link  NICE TA 323 Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
    Link  NICE TA 439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
    Link  NICE TA 439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
    Link  NICE TA 473: Head and neck cancer (squamous cell carcinoma) - cetuximab
       
    08.01.05  Crisantaspase
    08.01.05  Dacarbazine and Temozolomide
    Cytotoxic Drug Dacarbazine
    View adult BNF View SPC online
    Formulary
    Red

    Injection: 500mg

     
       
    Cytotoxic Drug Streptozocin
    View adult BNF View SPC online
    Formulary
    Red

    unlicensedunlicensed Injection: 1g (only available on a named patient basis)

     
       
    Cytotoxic Drug Temozolomide
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Capsules: 5mg, 20mg, 100mg, 250mg

     
    Link  NICE TA 23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
    Link  NICE TA 121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
       
    08.01.05  Erlotinib
    Cytotoxic Drug Erlotinib (Tarceva® )
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Tablets: 25mg, 100mg & 150mg

     
    Link  NICE TA 227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)
    Link  NICE TA 258: Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)
    Link  NICE TA 374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
       
    08.01.05  Hydroxycarbamide
    Hydroxycarbamide
    View adult BNF View SPC online
    Formulary
    Red

    Capsules: 500mg
    unlicensedunlicensed Suspension: 500mg in 5ml

     
       
    08.01.05  Imatinab to top
    08.01.05  Ipilimumab
    Ipilimumab
    View adult BNF View SPC online
    Formulary
    Red

    Vial for preparing IV infusion: 50mg

     
    Link  NICE TA 268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
    Link  NICE TA 319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
    Link  NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
    Link  NICE TA 400: Nivolumab in combination with ipilimumab for treating advanced melanoma
       
    08.01.05  Mitotane
    Mitotane
    View adult BNF View SPC online
    Formulary
    Red

    Tablets: 500mg

     
       
    08.01.05  Panitumumab
    08.01.05  Pentostatin
    08.01.05  Platinum compounds to top
    Cytotoxic Drug Carboplatin
    View adult BNF View SPC online
    Formulary
    Red

    Injections: 50mg in 5ml, 450mg in 45ml

     
       
    Cytotoxic Drug Cisplatin
    View adult BNF View SPC online
    Formulary
    Red

    Injection: 50mg

     
       
    Cytotoxic Drug Oxaliplatin
    View adult BNF View SPC online
    Formulary
    Red

    Injections: 50mg, 100mg

     
    Link  NICE TA 100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
       
    08.01.05  Porfimer sodium and temoporfin
    08.01.05  Procarbazine
    Cytotoxic Drug Procarbazine
    View adult BNF View SPC online
    Formulary
    Red

    Capsules: 50mg

     
       
    08.01.05  Protein kinase inhibitors
    Afatinib
    View adult BNF View SPC online
    Formulary
    Red

    Film coated tablets: 20mg, 30mg, 40mg, 50mg

     
    Link  NICE TA 310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
       
    Cytotoxic Drug AlectinibBlack Triangle (Alecensa®)
    View adult BNF View SPC online
    Formulary
    Red
    NHS England
    150mg capsules 
    Link  NICE TA 536: Alectinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
       
    Cytotoxic Drug Brigatinib (Alunbrig®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
  • Approved for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults who have already had crizotinib in line with NICE 
  • Link  NICE TA 570: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
       
    Cytotoxic Drug Cabozantinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
  • Approved for use in untreated advanced renal cell carcinoma in line with NICE and NHS England Commissioning Policy 
  • Link  NICE TA 542: Cabozantinib for untreated advanced renal cell carcinoma
       
    Crizotinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Capsules: 200mg, 250mg

     
    Link  NICE TA 406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
    Link  NICE TA 422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
    Link  NICE TA 529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
       
    Dacomitinib (Vizimpro®)
    View adult BNF View SPC online
    Formulary
    Red
    NHS England

    Dacomitinib is recommended, within its marketing authorisation, as an option for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) in adults. It is recommended only if the company provides it according to the commercial arrangement.

     
    Link  NICE TA 595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
       
    Cytotoxic Drug Dasatinib
    View adult BNF View SPC online
    Formulary
    Red

    Tablets: 20mg, 50mg

     
    Link  NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
    Link  NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
       
    Everolimus (Votubia®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Capsules: 2.5mg, 5mg, 10mg


    -Approved for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in accordnace line with NHS England Commissioning Policy
    -a
    pproved for the treatment of angiomyolipomas associated with tuberous sclerosis in line with NHS England Commissioning Policy


    Tablets: 5mg and 10mg


    - Clinical Commissioning Policy: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex
    - Approved, in combination with exemestane, for the treatment of advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer in postmenopausal women in accordance with NICE
    - Approved for the treatment of advanced breast cancer after endocrine therapy in line with NICE.
    -Approved for the treatment of advanced renal cell carcinoma after previous treatment in line with NICE


     

     
    Link  NICE TA 421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
    Link  NICE TA 432: Everolimus for advanced renal cell carcinoma after previous treatment
    Link  NICE TA 449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
       
    Gefitinib (Iressa®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Tablets: 250mg

     
    Link  NICE TA 192: Lung cancer (non-small-cell, first line) - gefitinib
    Link  NICE TA 374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
       
    Cytotoxic Drug Imatinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Capsules: 100mg & 400mg

     
    Link  NICE TA 70: Leukaemia (chronic myeloid) - imatinib
    Link  NICE TA 86: Gastro-intestinal stromal tumours (GIST) - imatinib
    Link  NICE TA 209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
    Link  NICE TA 326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
    Link  NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
    Link  NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
       
    Larotrectinib
    View adult BNF View SPC online View SMC online
    Formulary
    Red
    Cancer Drugs Fund

    Oral solution: 20mg/mL

    Recommended for use according to NICE criteria (TA630)

     
    Link  NICE TA 630: Larotrectinib for treating NTRK fusion-positive solid tumours
       
    Lorlatinib
    View adult BNF View SPC online View SMC online
    Formulary
    Red
    NHS England

    Tablets: 25mg, 100mg

     

    Recommended for use according to NICE criteria (TA628)

     
    Link  NICE TA 628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
       
    Nilotinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Capsules: 150mg, 200mg

     
    Link  NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
    Link  NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
       
    Nintedanib (Vargatef®)
    View adult BNF View SPC online
    Formulary
    Red

    Soft capsules: 100mg, 150mg

     
    Link  NICE TA 347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
    Link  NICE TA 379: Nintedanib for treating idiopathic pulmonary fibrosis
       
    Pazopanib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Tablets: 200mg, 400mg

     
    Link  NICE TA 215: Renal cell carcinoma (first line metastatic) - pazopanib
       
    Regorafenib (Stivarga® )
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Tablets: 40mg

     
    Link  NICE TA 488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
    Link  NICE TA 555: Regorafenib for previously treated advanced hepatocellular carcinoma
       
    Sorafenib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Tablets: 200mg

     
    Link  NICE TA 474: Sorafenib for treating advanced hepatocellular carcinoma
       
    Sunitinib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Capsules: 50mg 100mg, 400mg

     
    Link  NICE TA 169: Renal cell carcinoma - sunitinib
    Link  NICE TA 178: Renal cell carcinoma
    Link  NICE TA 179: Gastrointestinal stromal tumours - sunitinib
       
    Trifluridine and tipiracil
    View adult BNF View SPC online
    Formulary
    Red

    Tablets: 15mg/6.14mg, 20mg/8.19mg -approved for previously treated metastatic colorectal cancer in adults in line with NICE and NHS England Commissioning Policy

     
    Link  NICE TA 405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
       
    Vemurafenib
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Tablets: 240mg

     
    Link  NICE TA 269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
    Link  NICE TA 414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
       
    Venetoclax (Venclyxto®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Tablets: 10 mg, 50 mg & 100 mg

     
    Link  NICE TA 561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
    Link  NICE TA 663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
       
    08.01.05  Taxanes
    Cytotoxic Drug Abraxane® (Paclitaxel)
    View adult BNF View SPC online
    Formulary
    Red

    Powder for suspension for infusion: 5mg - restricted for use within its current license for metastatic breast cancer patients who cannot tolerate standard taxanes.

     
    Link  NICE TA 476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
       
    Cytotoxic Drug Cabazitaxel
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Concentrate for IV infusion: 40mg/1ml

     
    Link  NICE TA 391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
       
    Cytotoxic Drug Docetaxel
    View adult BNF View SPC online
    Formulary
    Red

    Injections: 20mg, 80mg

     
    Link  NICE TA 101: Prostate cancer (hormone-refractory) - docetaxel
       
    Cytotoxic Drug Paclitaxel
    View adult BNF View SPC online
    Formulary
    Red

    Concentrate for preparing IV infusion: 30mg in 5ml, 100mg in 16.7ml and 150mg in 25ml

     
    Link  NICE NG 101: Early and locally advanced breast cancer: diagnosis and management
    Link  NICE TA 55: Ovarian cancer - paclitaxel (review)
    Link  NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
       
    08.01.05  Topoisomerase I inhibitors to top
    Cytotoxic Drug Irinotecan
    View adult BNF View SPC online
    Formulary
    Red

    Injection: 40mg in 2ml & 100mg in 5ml

     
       
    Cytotoxic Drug Topotecan
    View adult BNF View SPC online
    Formulary
    Red

    Capsules: 0.25mg, 1mg capsules
    Vials: 1mg, 4mg

     
    Link  NICE TA 183: Cervical cancer (recurrent) - topotecan
    Link  NICE TA 184: Lung cancer (small-cell) - topotecan
    Link  NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
       
    08.01.05  Trabectedin
    Cytotoxic Drug Trabectedin (Yondelis®)
    View adult BNF View SPC online
    Formulary
    Red

    Injection: 250microgram

     
    Link  NICE TA 185: Soft tissue sarcoma - trabectedin
    Link  NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
       
    08.01.05  Trastuzumab
    Cytotoxic Drug Pertuzumab (Perjeta®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Vial: 420mg

     
    Link  NICE TA 509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
    Link  NICE TA 569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
       
    Cytotoxic Drug Trastuzumab (Herceptin®)
    View adult BNF View SPC online
    Formulary
    Red

    Vial for preparing IV infusion: 150mg
    Injection: 600mg s/c injection

     
    Link  NICE TA 101: Early and locally advanced breast cancer: diagnosis and management
    Link  NICE TA 208: Gastric cancer (HER2-positive metastatic) - trastuzumab
    Link  NICE TA 257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
    Link  NICE TA 34: Breast cancer - trastuzumab
       
    Cytotoxic Drug Trastuzumab emtansine (Kadcyla®)
    View adult BNF View SPC online
    Formulary
    Red
    Cancer Drugs Fund
     
    Link  NICE TA 235: Osteosarcoma - mifamurtide
    Link  NICE TA 632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
       
    08.01.05  Tretinoin
    Tretinoin
    View adult BNF View SPC online
    Formulary
    Red

    Capsules: 10mg

     
       
    08.01.05  Vismodegib
    08.02  Drugs affecting the immune response to top
    Blinatumomab (Blincyto®)
    View adult BNF View SPC online
    Formulary
    Red

    Vials: 38.5microgram

     
    Link  NICE TA 450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
    Link  NICE TA 589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
       
    08.02  Immunosuppressant therapy
    08.02.01  Antiproliferative immunosuppressants
    Cytotoxic Drug Azathioprine
    View adult BNF View SPC online
    Formulary
    Amber

    Tablets: 25mg & 50mg
    unlicensedunlicensed Suspension: 50mg in 5ml
    Injection: 50mg

     
       
    Mycophenolate Mofetil
    View adult BNF View SPC online
    Formulary
    Amber
    High Cost Medicine

    Capsules: 250mg
    Tablets: 500mg
    Oral suspension: 1g in 5ml (200mg/ml)
    Vial for preparing IV infusion: 500mg

     
    Link  NICE TA481: Immunosuppressive therapy for kidney transplant in adults
       
    Mycophenolate Sodium (Myfortic®)
    View adult BNF View SPC online
    Formulary
    Amber

    E/C tablets: 180mg & 360mg
    – 2nd line therapy in patients who do not tolerate mycophenolate mofetil

     
    Link  NICE TA481: Immunosuppressive therapy for kidney transplant in adults
       
    08.02.02  Corticosteroids and other immunosuppressants
    Antithymocyte immunoglobulin (horse)
    View adult BNF View SPC online
    Formulary
    Red

    unlicensedunlicensed Injection: 250mg in 5ml -NETAG approved for aplastic anaemia in adults

     
       
    Antithymocyte immunoglobulin (rabbit)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Injection: 25mg injection
    – used in the management of transplant rejection

     
       
    Basiliximab (Simulect®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Vial for preparing IV infusion: 20mg


    -approved for limited use in adult renal translplant patients with high risk of acute organ rejection


    -approved for severe graft versus host disease post haematopoietic stem cell transplantation


     

     
    Link  NICE TA 481: Immunosuppressive therapy for kidney transplant in adults
    Link  NICE TA 482: Immunosuppressive therapy for kidney transplant in children and young people
       
    Ciclosporin (Neoral®)
    View adult BNF View SPC online
    Formulary
    Amber
    High Cost Medicine

    Capsules: 10mg, 25mg, 50mg & 100mg
    Sugar free oral solution (oily): 100mg in 1ml

     
       
    Ciclosporin (Sandimmun®)
    View adult BNF View SPC online
    Formulary
    Amber

    Original oral formulations Sandimmun supplied on request for patients who cannot take Neoral
    unlicensedunlicensed Capsules: 25mg & 100mg
    Sugar-free oral solution (oily): 100mg in 1ml

     
       
    Ciclosporin (Sandimmun®)
    View adult BNF View SPC online
    Formulary
    Red

    IV Infusion: 50mg in 1ml & 250mg in 5ml concentrate (oily)

     
       
    Cytotoxic Drug Sirolimus
    View adult BNF View SPC online
    Formulary
    Amber
    High Cost Medicine

    Tablets: 1mg & 2mg
    Oral solution: 1mg per ml

     
    Link  NICE TA 482: Immunosuppressive therapy for kidney transplant in children and young people
       
    Tacrolimus
    View adult BNF View SPC online
    Formulary
    Amber

    500 microgram Capsules: 1mg & 5mg (Prograf & Adoport)
    unlicensedunlicensed Oral suspension: 5mg/5mL  
    RED - Concentrate for preparing IV infusion: 5mg in 1 ml
    - approved for renal transplantation in children and adolescents in line with NICE

     

    MR Capsules (Advagraf): 500microgram, 1mg, 3mg & 5mg
    - only approved for use for prophylaxis of organ rejection in kidney and liver transplantation. Advagraf® is approved for use in patients who are currently prescribed Prograf, and de novo patients should be prescribed Adoport®.

     

    MR tablets (Envarsus): 750microgram, 1mg, 4mg
    - approved for the treatment of renal and liver transplant patients who are suffering from neurotoxicity with other formulations or for patients requiring large doses of tacrolimus.

     
    Link  NICE TA 482: Immunosuppressive therapy for kidney transplant in children and young people
       
    08.02.03  Anti-lymphocyte monoclonal antibodies
    Alemtuzumab
    View adult BNF View SPC online
    Formulary
    Red

    Concentrate for IV infusion: 30mg in 1ml
    - for use in lymphocytic leukaemia & prevention of graft vs. host disease on bone marrow transplant patients
    -approved for use in high-risk kidney and pancreas transplantation


    Concentrate for IV infusion 12mg in 1.2ml
    -approved as an option for treating adults with active relapsing– remitting multiple sclerosis in line with NICE (subject to NHS ENGLAND funding)


     

     
    Link  NICE TA 312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis
       
    Isatuximab (Sarcusa®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Vill: concentrate for infusion 100 mg/5 mL and 500 mg/25 mL

     
    Link  NICE TA 658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
       
    Obinutuzumab (Gazyvaro ®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Concentrate for IV infusion: 1000mg in 40ml


    -for use in chronic lymphocytic leukaemia in combination with chlorambucil in patients who have co-morbitities that make fulldose fludarabinebased therapy unsuitable for them, only if bendamustinebased therapy is not suitable and the company provides obinutuzumab with the discount agreed in the patient access scheme in line with NICE (subject to NHS England funding)

     
    Link  NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
    Link  Obinutuzumab for untreated advanced follicular lymphoma (TA513 ) 21.3.18
       
    OcrelizumabBlack Triangle (Ocrevus®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    Solution for infusion 30mg per 1mL 
    Link  NICE TA 533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
    Link  NICE TA 585: Ocrelizumab for treating primary progressive multiple sclerosis
    Link  NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
       
    Rituximab
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Concentrate for IV infusion: 100mg in 10ml & 500mg in 50ml


    -for musculoskeletal indications see chapter 10
    -approved for first line use in NHL in combination with CHOP in line with NICE
    -approved for maintenance therapy in follicular NHL that has responded to first line induction therapy with rituximab in combination with chemotherapy in line with NICE
    -approved for stage III and IV follicular lymphoma in previously untreated people in line with NICE
    -approved for replased or refractory follicular NHL in line with NICE
    -approved for Post-transplant lymphoproliferative disease
    - approved for first line use in CLL in combination with fludarabine and cyclophosphamide in line with  NICE
    -approved for combination with fludarabine and cyclophosphamide for relapsed or refractory CLL in line with NICE
    -approved for autoimmune haematological conditions (where conventional treatments have failed)
    – Autoimmune haemolytic anaemia
    (AIHA), Evans syndrome, pure red cell aplasia (PRCA), acquired haemophilia A & thrombocytopenia purpura (TTP).
    - Combination with bendamustine for first line use in CLL (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate.
    - a
    pproved for vasculitis (including Wegener’s granulomatosis in adults and children) that has not responded adequately to conventional treatment (e.g. corticosteroids, cyclophosphamide) NICE and additional NHS England criteria
    -NECDAG approved for the treatment of NLPHL
    -NECDAG approved for newly diagnosed mantle cell NHL in patients aged <60 years old approved in combination with bendamustine for first line use in CLL (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate NICE
    -NECDAG approved in combination with bendamustine for patients with CLL not fit for FCR chemotherapy or for patients who relapse within 2 years of FCR chemotherapy and not fit for alemtuzumab.
    -NECDAG approved with salvage chemotherapy for patients relapsing > 12 months post 1st line -therapy with R-CHOP
    -NECDAG approved with a standard NHL induction regimen in patients who cannot be given an anthracycline. Rituximab with other chemotherapy regimens is an alternative treatment option e.g. DECC, CVP for this group of patients, as part of their first line therapy. Also in addition to the MACOP-B regimen for the small number of young patients with DLBCL, subtype Primary Mediastinal B cell Lymphoma
    -NECDAG approved for the treatment of hairy Cell Leukaemia (HCL) or Hairy cell Leukaemia varian (HCL-v) who:


            -relapse early after purine analogue therapy (< 2 years post treatment)
            -are refractory to purine analogues.
    -NTAG approved for the treatment of immune (idiopathic) thrombocytopenic purpura (ITP) in adults and children NTAG
    -approved for the treatment of immunobullous disease in line with NHS England Commissioning Policy



    SC injection: 1.4g solution


    -approved for use as maintenance single agent therapy in FL, mantle cell lymphoma, marginal zone lymphoma and lymphoplasmacytic lymphoma in line with NHS ENGLAND SSC1434

     
    Link  NICE TA 308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
    Link  NICE TA 627: Lenalidomide with rituximab for previously treated follicular lymphoma
    Link  NICE TA137: Lymphoma (follicular non-Hodgkin's) - rituximab
    Link  NICE TA174: Leukaemia (chronic lymphocytic, first line) - rituximab
    Link  NICE TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab
    Link  NICE TA226: Lymphoma (follicular non-Hodgkin’s) - rituximab
    Link  NICE TA243: Follicular lymphoma - rituximab (review)
       
    08.02.04  Other immunomodulating drugs to top
    BCG Connaught
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Vial: 81mg for bladder instillation

     
       
    Brodalumab (Kyntheum ® )
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    210mg solution for infusion

    Brodalumab for treating moderate to severe plaque psoriasis (TA511) 21.3.18

     
       
    Cemiplimab (Libtayo®)
    View adult BNF View SPC online
    Formulary
    Red
    Cancer Drugs Fund

    Cemiplimab (Libtayo®) is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic cutaneous squamous cell carcinoma in adults when curative surgery or curative radiotherapy is not appropriate.

    It is recommended only if the conditions in the managed access agreement are followed.

     
    Link  NICE TA 592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
       
    Dimethyl fumarate
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Capsules: 120mg, 240mg

     
    Link  NICE TA 303: Teriflunomide for treating relapsing–remitting multiple sclerosis
    Link  NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
       
    Cytotoxic Drug Dinutuximab beta (Qarziba®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
  • 20mg/4.5mL concentrate for solution for infusion
  • Approved for the treatment of high-risk neuroblastoma in people aged 12 months and over in line with NICE 
  • Link  NICE TA 538: Dinutuximab beta for treating neuroblastoma
       
    Durvalumab (Imfinzi®)
    View adult BNF View SPC online
    Formulary
    Red
    Cancer Drugs Fund

    Durvalumab (Imfinzi®) monotherapy is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced unresectable non-small cell lung cancer in adults whose tumours express PD‑L1 on at least 1% of tumour cells and whose disease has not progressed after platinum-based chemoradiation only if:

    • they have had concurrent platinum-based chemoradiation, and
    • the conditions in the managed access agreement are followed.
     
    Link  NICE TA 578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
       
    Fingolimod
    View adult BNF View SPC online
    Formulary
    Red

    Capsules: 500microgram - - approved for the treatment of highly active relapsing–remitting multiple sclerosis in line with NICE - approved for patients who have progressed on glatiramer acetate and for those patients who are at high risk of progressive multifocal leukoencephalopathy (PML) in line withNHS EnglandClinical Commissioning Policy

     
    Link  NICE TA 254: Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis
       
    Lenalidomide
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Capsules: 5mg, 10mg, 15mg, & 25mg

     
    Link  NICE TA 586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
    Link  NICE TA 587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma
    Link  NICE TA171: Multiple myeloma - lenalidomide
    Link  NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
    Link  NICE TA627: Lenalidomide with rituximab for previously treated follicular lymphoma
       
    Mifamurtide
    View adult BNF View SPC online
    Formulary
    Red

    Vial: 4mg

     
    Link  NICE TA 235: Mifamurtide for the treatment of osteosarcoma
       
    Nivolumab
    View adult BNF View SPC online
    Formulary
    Red

    Concentrate for IV infusion: 10mg in 1ml concentrate for IV infusion as (4ml, 10ml & 24ml vials)

     

     

     

    For the treatment of locally advanced or metastatic squamous nonsmall cell lung cancer (NSCLC) after prior chemotherapy in adults

     
    Link  NICE TA 417: Nivolumab for previously treated advanced renal cell carcinoma
    Link  NICE TA 462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
    Link  NICE TA 581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
    Link  NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
    Link  NICE TA 400: Nivolumab in combination with ipilimumab for treating advanced melanoma
    Link  NICE TA 558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
    Link  NICE TA 655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy
       
    Pomalidomide (Imnovid®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Capsules: 1mg, 2mg, 3mg, 4mg

     
    Link  NICE TA 427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
       
    Siponimod (Mayzent®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Tablet: 250 micrograns and 2 mg

     
    Link  NICE TA 656: Siponimod for treating secondary progressive multiple sclerosis
       
    Teriflunomide
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Film coated tablets: 14mg

     
    Link  NICE TA303: Teriflunomide for relapsing remitting MS
       
    Thalidomide
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Capsules: 50mg


    - approved in combination with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma in line with NICE
    - approved for the treatment of bleeding from bowel angiodysplasia in patients with an inherited/acquired bleeding disorder on specialist advice only.
    -approved for the treatment of severe epistaxis as a result of hereditary haemorrhagic telangiectasia (HHT) who have failed all other treatments.

     
    Link  NICE TA 228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
       
    08.02.04  Interferon Alfa
    Interferon alfa-2b
    View adult BNF View SPC online
    Formulary
    Red

    Multidose pen injections: 10 mega units, 30 mega units

     
       
    Peginterferon alfa-2a
    View adult BNF View SPC online
    Formulary
    Red

    Injections in prefilled syringes 135 microgram, 180 microgram
    Prefilled pens: 135 micrograms and 180 micrograms

     
    Link  NICE TA 106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
    Link  NICE TA 200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
    Link  NICE TA 300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
    Link  NICE TA 75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
    Link  NICE TA 96: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
       
    Peginterferon alfa-2b
    View adult BNF View SPC online
    Formulary
    Red

    Prefilled injection pens: 50, 80, 100, 120, 150 micrograms
    -approved for chronic hepatitis C as peginterferon alffa 2a

     
       
    08.02.04  Interferon beta
    Interferon beta-1a
    View adult BNF View SPC online
    Formulary
    Red

    Prefilled pen (Avonex): 30 micrograms (6 million units)
    Prefilled pen (Rebif): 22 microgram (6 million units) & 44 microgram (12 million units)
    Cartridge for use in rebismart device: 22 microgram per 0.5ml and 44 microgram per 0.5ml
    Prefilled pen: 44 microgram per 0.5ml (Rebidose)
    -approved for use when the cartridges and prefilled syringes are unsuitable.

     
       
    Interferon beta-1b
    View adult BNF View SPC online
    Formulary
    Red

    Vials for preparing 750 microgram in 3ml injection (Betaferon)
    Vials for preparing 250 microgram in 1ml injection (Extavia)

     
       
    Peginterferon beta-1a
    View adult BNF View SPC online
    Formulary
    Red

    Prefilled pen: 125 microgram (Plegridy)

     
    Link  NICE TA624:Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis
       
    08.02.04  Aldesleukin
    08.02.04  Glatiramer acetate
    Glatiramer Acetate
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Prefilled syringe injection: 20mg

     
    Link  NICE TA 527: Beta interferons and glatiramer acetate for treating multiple sclerosis
       
    08.02.04  Natalizumab to top
    Natalizumab
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Vial for preparing infusions: 300mg in 15ml (20mg/ml)
    - approved for rapidly evolving severe relapsing remitting multiple sclerosis in line with NICE

     
    Link  NICE TA127: Multiple sclerosis - natalizumab
       
    08.03  Sex hormones and hormone antagonists in malignant disease
    08.03.01  Oestrogens
    Diethylstilbestrol
    View adult BNF View SPC online
    Formulary
    Green +

    Tablets: 1mg

     
       
    08.03.02  Progestogens
    Medroxyprogesterone Acetate
    View adult BNF View SPC online
    Formulary

    Tablets: 100mg & 200mg
    Injections: 500mg in 2.5ml

     
       
    Megestrol Acetate
    View adult BNF View SPC online
    Formulary

    Tablets: 160mg

     
       
    Norethisterone
    View adult BNF View SPC online
    Formulary

    Tablets: 5mg

     
       
    08.03.03  Androgens
    08.03.04  Hormone antagonists to top
    08.03.04.01  Breast cancer
    Abemaciclib (Verzenios®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England

    Approved for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in adults who have not had endocrine-based therapy before in accordance with NICE

    Abemaciclib with fulvestrant is recommended for use within the Cancer Drugs Fund as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)‑negative locally advanced or metastatic breast cancer in people who have had endocrine therapy only if:

    • exemestane plus everolimus would be the most appropriate alternative and

    • the conditions in the managed access agreement for abemaciclib with fulvestrant are followed.

     
    Link  NICE TA 563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
    Link  NICE TA 579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
       
    Anastrozole
    View adult BNF View SPC online
    Formulary
    Green +

    Tablets: 1mg

     
    Link  NG101: Early and locally advanced breast cancer: diagnosis and management
       
    Exemestane
    View adult BNF View SPC online
    Formulary
    Green +

    Tablets: 25mg

     
    Link  NG101:Early and locally advanced breast cancer: diagnosis and management
       
    Letrozole
    View adult BNF View SPC online
    Formulary
    Green +

    Tablets: 2.5mg

     
    Link  NG101: Early and locally advanced breast cancer: diagnosis and management
       
    Palbociclib
    View adult BNF View SPC online
    Formulary
    Red

    Capsules: 125mg

     
    Link  NICE TA 495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
       
    Ribociclib
    View adult BNF View SPC online
    Formulary
    Red

    Tablets: 200mg

     
    Link  NICE TA 496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
    Link  NICE TA 593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
       
    Tamoxifen
    View adult BNF View SPC online
    Formulary
    Green +

    Tablets: 10mg & 20mg
    Sugar-free oral solution: 10mg in 5ml

     
       
    Zoledronic acid (Zometa)
    View adult BNF View SPC online
    Formulary
    Red

    Concentrate for intravenous infusion (vial): 4mg


    Indication: prevention of treatment associated osteoporosis and to reduce the risk of recurrence in post-menopausal patients with early breast cancer (note: unlicensed for this indication)

     
       
    08.03.04.02  Prostate cancer and gonadorelin analogues
     note 

    Clinicians are encouraged to prescribe the least expensive product that is clinically appropriate

    08.03.04.02  Gonadorelin analogues
    Degarelix (Firmagon®)
    View adult BNF View SPC online
    Formulary

    Green+ Traffic Light OR Amber Traffic Light

     

    Dependent on patient disease state (classified by module; this will be communicated by secondary care).

    Module 1 - medication is Green+

    Module 2 - medication is Amber

     

    Vials (with diluent): 80mg & 120mg

     
    Link  NICE TA 404: Degarelix for treating advanced hormone-dependent prostate cancer
       
    08.03.04.02  Anti-androgens
    Abiraterone
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Tablets: 250mg

     
    Link  NICE TA 387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
    Link  NICE TA259: Abiraterone for castration resistant prostate cancer
       
    Bicalutamide
    View adult BNF View SPC online
    Formulary
    Green +

    Tablets: 50mg, 150mg 
    -initiated with specialist advice

     
       
    Buserelin
    View adult BNF View SPC online
    Formulary
    Green +

    Injection: 5mg in 5ml
    Metered dose nasal sprays 150 microgram

     
       
    Cyproterone
    View adult BNF View SPC online
    Formulary
    Green +

    Tablets: 50mg & 100mg

     
       
    Darolutamide (Nubeqa®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Tablets: 300 mg

     
    Link  NICE TA 660: Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer
       
    Enzalutamide
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Tablets: 40mg

     
    Link  NICE TA316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
    Link  NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
       
    Flutamide
    View adult BNF View SPC online
    Formulary
    Green +

    Tablets:  250mg

     
       
    Goserelin
    View adult BNF View SPC online
    Formulary


    Green+ Traffic Light OR Amber Traffic Light

    Dependent on patient disease state (classified by module; this will be communicated by secondary care).

    Module 1 - medication is Green+

    Module 2 - medication is Amber

     

    Implants: 3.6mg & 10.8mg

     
       
    Leuprorelin Acetate
    View adult BNF View SPC online
    Formulary


    Green+ Traffic Light OR Amber Traffic Light

     

    Dependent on patient disease state (classified by module; this will be communicated by secondary care).

    Module 1 - medication is Green+

    Module 2 - medication is Amber

     

    Prefilled syringes: 3.75mg, 11.25mg

     
       
    Triptorelin (Gonapeptyl Depot®)
    View adult BNF View SPC online
    Formulary


    Green+ Traffic Light OR Amber Traffic Light

    Dependent on patient disease state (classified by module; this will be communicated by secondary care).

    Module 1 - medication is Green+

    Module 2 - medication is Amber

     

    IM injection: 3mg, 11.25mg and 22.5mg

     
       
    08.03.04.03  Somatostatin analogues to top
    Lanreotide
    View adult BNF View SPC online
    Formulary
    Green +
    High Cost Medicine

    Long acting Injection: 30mg
    Autogel injections: 60mg, 90mg & 120mg

     

    Green Plus for palliative care indications (leaflet in development)

     
       
    Lanreotide
    View adult BNF View SPC online
    Formulary
    Red

    Long acting Injection: 30mg
    Autogel injections: 60mg, 90mg & 120mg

    RED for acromegaly, neuroendocrine tumour and carcinoid

     
       
    Octreotide
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Injections: 50, 100 & 500 microg. in 1ml & 1mg in 5ml
    Long-acting injections: 10mg, 20mg & 30mg

    RED for acromegaly, neuroendocrine tumour and carcinoid

     
       
    Octreotide
    View adult BNF View SPC online
    Formulary
    Green +
    High Cost Medicine

    Injections: 50, 100 & 500 microg. in 1ml & 1mg in 5ml
    Long-acting injections: 10mg, 20mg & 30mg

     

    GREEN PLUS for palliative care indications (leaflet in development)

     
       
     ....
     Non Formulary Items
    Aldesleukin  (Proleukin®)

    View adult BNF View SPC online
    Non Formulary
    High Cost Medicine
     
    Amifostine  (Ethyol®)

    View adult BNF View SPC online
    Non Formulary
     
    Belatacept  (Nulojix®)

    View adult BNF View SPC online
    Non Formulary
    High Cost Medicine
     
    Bexarotene  (Targretin®)

    View adult BNF View SPC online
    Non Formulary
     
    Calcium Leofolinate  (Isovorin®)

    View adult BNF View SPC online
    Non Formulary
     
    Canakinumab  (Ilaris®)

    View adult BNF View SPC online
    Non Formulary
    High Cost Medicine
     
    Cediranib  (Recentin®)

    View adult BNF View SPC online
    Non Formulary
     
    Cytotoxic Drug  Clofarabine  (Evoltra®)

    View adult BNF View SPC online
    Non Formulary
    High Cost Medicine
    Cancer Drugs Fund
     
    Cobimetinib  (Cotellic®)

    View adult BNF View SPC online
    Non Formulary
     
    Crisantaspase  (Erwinase®)

    View adult BNF View SPC online
    Non Formulary
     
    Daclizumab  (Zenapax®)

    View adult BNF View SPC online
    Non Formulary
     
    Cytotoxic Drug  Decitabine  (Dacogen®)

    View adult BNF View SPC online
    Non Formulary
    High Cost Medicine
    Link  NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270)
     
    Disodium Folinate  (Sodiofolin®)

    View adult BNF View SPC online
    Non Formulary
     
    Disodium Levofolinate

    View adult BNF View SPC online
    Non Formulary
     
    Ethinylestradol

    View adult BNF View SPC online
    Non Formulary
     
    Fampridine

    View adult BNF View SPC online
    Non Formulary
    High Cost Medicine
     
    Histrelin  (Vantas®)

    View adult BNF View SPC online
    Non Formulary
     
    Ixazomib  (Ninlaro®)

    View adult BNF View SPC online
    Non Formulary
     
    Modigraf®

    View adult BNF View SPC online
    Non Formulary
     
    Necitumumab

    View adult BNF View SPC online
    Non Formulary
    High Cost Medicine
     
    Nelarabine  (Atriance®)

    View adult BNF View SPC online
    Non Formulary
    High Cost Medicine
    Cancer Drugs Fund
     
    Palifermin  (Kepivance®)

    View adult BNF View SPC online
    Non Formulary
     
    Cytotoxic Drug  Panitumumab  (Vectibix®)

    View adult BNF View SPC online
    Non Formulary
    High Cost Medicine
    Cancer Drugs Fund
     
    Pemrolizumab  (Keytruda®)

    View adult BNF View SPC online
    Non Formulary
     
    Cytotoxic Drug  Pentostatin  (Nipent®)

    View adult BNF View SPC online
    Non Formulary
     
    Porfimer Sodium  (Photofrin ®)

    View adult BNF View SPC online
    Non Formulary
     
    Prednisolone

    View adult BNF View SPC online
    Non Formulary
     
    Prednisolone

    View adult BNF View SPC online
    Non Formulary
     
    Prograf®

    View adult BNF View SPC online
    Non Formulary
     
    Cytotoxic Drug  Raltitrexed  (Tomudex®)

    View adult BNF View SPC online
    Non Formulary
     
    Sonidegib  (Odomzo®)

    View adult BNF View SPC online
    Non Formulary
     
    Temoporfin  (Foscan®)

    View adult BNF View SPC online
    Non Formulary
     
    Cytotoxic Drug  Tioguanine  (Lanvis®)

    View adult BNF View SPC online
    Non Formulary
     
    Toremifene  (Fareston®)

    View adult BNF View SPC online
    Non Formulary
     
    Cytotoxic Drug  Vandetanib  (Caprelsa®)

    View adult BNF View SPC online
    Non Formulary
    High Cost Medicine
    Cancer Drugs Fund
     
    Cytotoxic Drug  Vismodegib  (Erivedge®)

    View adult BNF View SPC online
    Non Formulary
    High Cost Medicine
    Cancer Drugs Fund
     
    Vosaroxin  (Qinprezo)

    View adult BNF View SPC online
    Non Formulary
    High Cost Medicine
     
      
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to SPCs
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Red

    Drugs for hospital use or use by a specialist within specialist centre only. Initiation and monitoring of treatment should remain under the total responsibility of the appropriate hospital clinician or specialist. These drugs should only be prescribed under the direct supervision of that clinician or specialist and are not suitable for shared care arrangements. The drug should be supplied via the hospital or specialist centre for the duration of treatment.   

    Amber

    These are specialist drugs which must be initiated by secondary care specialist prescribers, but with the potential to transfer prescribing to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care. For these drugs, in order to ensure patient safety, some aspects of care must remain with the specialist due to their complexity e.g. monitoring of disease or drug response. Other more routine aspects can be transferred to the GP e.g. monitoring of adverse effects and supply of the medicine. The specific responsibilities of the specialist and GP are defined in the shared care agreement for each drug. Shared care agreements are still under development for some amber drugs. Until these are available, it would be expected that any shared care request from secondary care to a GP would be accompanied by written information which defines prescribing and monitoring responsibilities. The hospital specialist should also provide the GP with enough information and support to allow the safe transfer and ongoing management of prescribing into primary care.   

    Green +

    Drugs which should usually be initiated in secondary care, or by a specialist clinician, but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case.  

    Green

    These are defined as new and established drugs, which may be prescribed, initiated, changed or maintained on FP10 by the GP and, if appropriate, discontinued without recourse to secondary care. N.B. DRUGS NOT IDENTIFIED IN THE FORMULARY BY A RED, AMBER OR GREEN+ SYMBOL ARE CLASSIFIED AS GREEN.   

    netFormulary